MPT: Ultra-Low Dose NOAC Aids Outcomes in Stable CVD

ACC Conference Reporter

ESC 2017 | BARCELONA — For stable atherosclerotic vascular disease, an ultra-low dose of rivaroxaban (Xarelto) improved cardiovascular outcomes when added to aspirin, although it also increased major bleeds, the COMPASS trial showed. Read More >>>

Keywords: ESC2017, ESC Congress


< Back to Listings